4.6 Article

Adenine base editing in an adult mouse model of tyrosinaemia

Journal

NATURE BIOMEDICAL ENGINEERING
Volume 4, Issue 1, Pages 125-130

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-019-0357-8

Keywords

-

Funding

  1. NCI NIH HHS [F31 CA224800, T32 CA203702, K22 CA181280, R01 CA195787, P30 CA014051] Funding Source: Medline
  2. NHGRI NIH HHS [RM1 HG009490] Funding Source: Medline
  3. NHLBI NIH HHS [DP2 HL137167, UG3 HL147367, P01 HL131471] Funding Source: Medline
  4. NIAID NIH HHS [U01 AI142756] Funding Source: Medline
  5. NIBIB NIH HHS [R01 EB022376] Funding Source: Medline
  6. NIGMS NIH HHS [R35 GM118062, T32 GM095450] Funding Source: Medline

Ask authors/readers for more resources

Intravenous delivery of an adenine base editor and a single-guide RNA for the Fah gene can correct an A>G splice-site mutation in an adult mouse model of tyrosinaemia. In contrast to traditional CRISPR-Cas9 homology-directed repair, base editing can correct point mutations without supplying a DNA-repair template. Here we show in a mouse model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine base editor (ABE) and a single-guide RNA (sgRNA) can correct an A>G splice-site mutation. ABE treatment partially restored splicing, generated fumarylacetoacetate hydrolase (FAH)-positive hepatocytes in the liver, and rescued weight loss in mice. We also generated FAH(+) hepatocytes in the liver via lipid-nanoparticle-mediated delivery of a chemically modified sgRNA and an mRNA of a codon-optimized base editor that displayed higher base-editing efficiency than the standard ABEs. Our findings suggest that adenine base editing can be used for the correction of genetic diseases in adult animals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available